Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
Protocole ID	CA233-0000
ClinicalTrials.gov ID	NCT06544655
Type(s) de cancer	Tumeurs solides
Phase	Phase I
Type étude	Clinique
Médicament	BMS-986484 en monothérapie ou en association avec le nivolumab
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dre Rahima Jamal
Coordonnateur(trice)	Adeline Hamon 514-890-8000 poste 30737
Statut	Actif en recrutement
Critètes d'éligibilité	Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN). Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1). Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Critètes d'exclusion	History of or with active interstitial lung disease or pulmonary fibrosis. Active, known, or suspected autoimmune disease. Serious uncontrolled medical disorders. New onset, non-catheter-associated venous thromboembolism within the past 6 months. Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec